Prostate cancer update: 2007

Current Opinion in Oncology

Volumn 20, Issue 3, 2008, Pages 294-299

  Lin, Amy M ^a   Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hormonal therapy; Prostate cancer; Risk and prevention; Taxane resistance

Indexed keywords

ATRASENTAN; CALCITRIOL; CLODRONIC ACID; DOCETAXEL; IXABEPILONE; MITOXANTRONE; PLACEBO; PREDNISONE; SATRAPLATIN; ZOLEDRONIC ACID;

ANDROGEN THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; GLEASON SCORE; HUMAN; NOMOGRAM; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; MASS SCREENING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; RISK FACTORS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 41949135296     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282f8b075     Document Type: Review

References (23)

1. Park SY, Murphy SP, Wilkens LR, et al. Calcium, vitamin D, and dairy product intake and prostate cancer risk: the Multiethnic Cohort Study. Am J Epidemiol 2007; 166:1259-1269.
2. Park Y, Mitrou PN, Kipnis V, et al. Calcium, dairy foods, and risk of incident and fatal prostate cancer: the NIH-AARP Diet and Health Study. Am J Epidemiol 2007; 166:1270-1279.
3. Platz EA, Leitzmann MF, Visvanathan K, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98:1819-1825.
4. D'Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol 2007; 8:21-25. Lower doses of finasteride decrease PSA levels to the same degree as higher doses of finasteride and should be a consideration when PSA screening for prostate cancer.
5. Kattan MW, Cuzick J, Fisher G, et al. Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer 2008; 112:69-74.
6. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29:1228-1242.
7. Patel AA, Chen MH, Renshaw AA, D'Amico AV. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA 2007; 298:1533-1538. Tertiary Gleason 5 tumors should be factored into the Gleason score sum as there appears to be a shorter time to biochemical recurrence in these patients.
8. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Eng J Med 2005; 352:1977-1984.
9. Wong YN, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006; 296:2683-2693. Elderly men with newly diagnosed localized prostate cancer may obtain survival benefit with active treatment rather than observation.
10. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8:475-487.
11. Mason MD, Sydes MR, Glaholm J, et al. Oral sodium clodronate for non-metastatic prostate cancer-results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 2007; 99:765-776.
12. Swanson GP, Hussey MA, Tangen CM, et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 2007; 25:2225-2229. In high-risk postprostatectomy patients, adjuvant radiotherapy appears to be more effective when administered at the lower PSA levels.
13. Van der Kwast TH, Bolla M, Van Poppel H, et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007; 25:4178-4186. High-risk postprostatectomy patients with a positive surgical margin may be a subgroup that benefits from adjuvant radiotherapy rather than observation.
14. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366:572-578.
15. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007; 177:540-545.
16. Freedland SJ, Humphreys EB, Mangold LA, et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 2007; 25:1765-1771. For patients with a biochemical recurrence following prostatectomy, PSA-DT can predict likelihood of prostate-cancer specific death versus competing causes of mortality.
17. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 25:2035-2041. This is the first comprehensive nomogram developed for salvage radiotherapy patients.
18. Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296:2329-2335.
19. Tsai HK, D'Amico AV, Sadetsky N, et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007; 99:1516-1524. This is the first study identifying elevated cardiovascular risk associated with ADT when used in conjunction with definitive local therapy, suggesting that maximizing cardiovascular health prior to initiating local therapy is warranted.
20. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007; 25:2420-2425. This is the first study suggesting that fatal cardiovascular events may occur earlier in time with the use of ADT.
21. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110:1959-1966.
22. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007; 25:669-674. This study serves a reminder that whereas initial phase II studies may show promise of survival benefit, the definitive phase III trial must be conducted before clinical practices change.
23. Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007; 110:556-563. This is the first prospective study defining the characteristics of taxane-resistant, metastatic HRPC.